Research programme- RNA based therapeutics - Merck/Orna Therapeutics
Latest Information Update: 10 Oct 2022
At a glance
- Originator Orna Therapeutics
- Developer Merck Sharp & Dohme; Orna Therapeutics
- Class Anti-infectives; Antineoplastics; RNA
- Mechanism of Action Protein synthesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Infections